Celgene Corporation (CELG): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation ( CELG) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole was unchanged today. By the end of trading, Celgene Corporation fell $3.18 (-2.3%) to $137.65 on average volume. Throughout the day, 2,895,313 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,884,700 shares. The stock ranged in price between $136.74-$141.20 after having opened the day at $141.03 as compared to the previous trading day's close of $140.83. Other companies within the Drugs industry that declined today were: Aastrom Biosciences ( ASTM), down 43.4%, Alimera ( ALIM), down 20.7%, Savient Pharmaceuticals ( SVNT), down 14.5% and Zalicus ( ZLCS), down 13.1%.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $58.4 billion and is part of the health care sector. Shares are up 81.1% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.